Adrian Bot, MD, PhD

Venture Partner

Adrian Bot, MD, PhD is a Venture Partner at Raven. Prior to Raven, he was the founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held senior leadership roles at Kite Pharma and Kite — a Gilead Company, including Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Previously, Dr. Bot served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. Dr. Bot is an inventor with multiple issued patents in the field of immunotherapy, and he authored or co-authored more than 200 peer reviewed manuscripts, abstracts, book chapters and monographs. He serves on the Board of Directors of Cartesian Therapeutics, Immuthera Bio and ImmunoScape, and serves as Advisor for AbbVie Inc, Stand Up 2 Cancer and other organizations. Dr. Bot participated in several exits to date: Kite Pharma initial public offering, Kite Pharma acquisition by Gilead Sciences and Capstan Therapeutics acquisition by AbbVie Inc. Dr. Bot is a biopharma executive with three decades of experience in research and development with a focus on immune, cell, gene therapy and nanomedicines, from start up to global, commercial stage companies. Dr. Bot holds an MD from University of Medicine and Pharmacy Timisoara, Romania and a PhD in Biomedical Sciences at Mount Sinai School of Medicine.